Oxford BioMedica PLC Total Assets
Oxford BioMedica PLC total assets. Based on the latest financial reports, Oxford BioMedica PLC (OXB) holds total assets worth GBX216.32 Million GBX (≈ $26.32K USD) as of June 2025. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. Also see Oxford BioMedica PLC (OXB) market capitalisation for the company's overall valuation and market capitalisation.
Total Assets of Oxford BioMedica PLC (1996–2024)
Total assets of Oxford BioMedica PLC from 1996 to 2024. This chart illustrates how Oxford BioMedica PLC's total assets have evolved over time, based on quarterly financial data. See OXB stock price for real-time trading data and today's change.
Oxford BioMedica PLC - Asset Composition Analysis
Oxford BioMedica PLC Total Assets Breakdown (December 2024)
Oxford BioMedica PLC total assets breakdown as of December 2024. Oxford BioMedica PLC's total assets of GBX216.32 Million consist of 57.5% current assets and 42.5% non-current assets.
| Asset Category | Amount (GBX) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | GBX0.00 | 26.2% |
| Accounts Receivable | GBX42.11 Million | 18.2% |
| Inventory | GBX13.57 Million | 5.9% |
| Property, Plant & Equipment | GBX0.00 | 0.0% |
| Intangible Assets | GBX29.22 Million | 12.6% |
| Goodwill | GBX0.00 | 0.0% |
Asset Composition Trend (1996–2024)
This chart illustrates how Oxford BioMedica PLC's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. Explore Oxford BioMedica PLC short-term liquidity ratio to assess how much short-term liquidity the company maintains relative to its equity base.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Oxford BioMedica PLC's current assets represent 57.5% of total assets in 2024, a decrease from 59.8% in 1996.
- Cash Position: Cash and equivalents constituted 26.2% of total assets in 2024, down from 56.6% in 1996.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 12.0% of total assets, a decrease from 39.0% in 1996.
- Asset Diversification: The largest asset category is accounts receivable at 18.2% of total assets.
Oxford BioMedica PLC Competitors by Total Assets
Key competitors of Oxford BioMedica PLC based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Samsung Biologics Co Ltd
KO:207940
|
Korea | ₩12.65 Trillion |
|
Verona Pharma plc
F:I9SA
|
Germany | €572.87 Million |
|
Asymchem Laboratories Tian Jin Co Ltd
SHE:002821
|
China | CN¥20.70 Billion |
|
Immunovant Inc
NASDAQ:IMVT
|
USA | $852.49 Million |
|
Shanghai Allist Pharmaceuticals Co. Ltd. A
SHG:688578
|
China | CN¥8.59 Billion |
|
Tubize-Fin
BR:TUB
|
Belgium | €1.99 Billion |
|
Shanghai RAAS Blood Products Co Ltd Class A
SHE:002252
|
China | CN¥37.46 Billion |
|
Amicus Therapeutics Inc
NASDAQ:FOLD
|
USA | $949.87 Million |
Oxford BioMedica PLC - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 1.89 | 2.35 | 2.89 |
| Quick Ratio | 1.67 | 2.07 | 2.79 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | GBX62.07 Million | GBX79.73 Million | GBX59.15 Million |
Oxford BioMedica PLC - Advanced Valuation Insights
This section examines the relationship between Oxford BioMedica PLC's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 26.86 |
| Latest Market Cap to Assets Ratio | 0.03 |
| Asset Growth Rate (YoY) | -8.2% |
| Total Assets | GBX231.64 Million |
| Market Capitalization | $8.02 Million USD |
Valuation Analysis
Below Book Valuation: The market values Oxford BioMedica PLC's assets below their book value (0.03x), which may indicate investor concerns about asset quality or future growth.
Significant Asset Reduction: Oxford BioMedica PLC's assets decreased by 8.2% over the past year, potentially indicating divestiture, restructuring, or challenging business conditions.
Annual Total Assets for Oxford BioMedica PLC (1996–2024)
The table below shows the annual total assets of Oxford BioMedica PLC from 1996 to 2024.
| Year | Total Assets | Change |
|---|---|---|
| 2024-12-31 | GBX231.64 Million ≈ $28.18K |
-8.20% |
| 2023-12-31 | GBX252.34 Million ≈ $30.70K |
-45.16% |
| 2022-12-31 | GBX460.18 Million ≈ $55.99K |
+93.98% |
| 2021-12-31 | GBX237.23 Million ≈ $28.86K |
+28.98% |
| 2020-12-31 | GBX183.93 Million ≈ $22.38K |
+49.62% |
| 2019-12-31 | GBX122.93 Million ≈ $14.96K |
+9.37% |
| 2018-12-31 | GBX112.40 Million ≈ $13.68K |
+71.86% |
| 2017-12-31 | GBX65.40 Million ≈ $7.96K |
+14.86% |
| 2016-12-31 | GBX56.94 Million ≈ $6.93K |
+9.82% |
| 2015-12-31 | GBX51.85 Million ≈ $6.31K |
+53.38% |
| 2014-12-31 | GBX33.80 Million ≈ $4.11K |
+147.76% |
| 2013-12-31 | GBX13.64 Million ≈ $1.66K |
-44.13% |
| 2012-12-31 | GBX24.42 Million ≈ $2.97K |
-6.41% |
| 2011-12-31 | GBX26.09 Million ≈ $3.18K |
+1.75% |
| 2010-12-31 | GBX25.64 Million ≈ $3.12K |
-41.65% |
| 2009-12-31 | GBX43.95 Million ≈ $5.35K |
+1.92% |
| 2008-12-31 | GBX43.12 Million ≈ $5.25K |
-29.50% |
| 2007-12-31 | GBX61.16 Million ≈ $7.44K |
+72.10% |
| 2006-12-31 | GBX35.54 Million ≈ $4.32K |
-27.83% |
| 2005-12-31 | GBX49.24 Million ≈ $5.99K |
+72.27% |
| 2004-12-31 | GBX28.58 Million ≈ $3.48K |
-22.14% |
| 2003-12-31 | GBX36.71 Million ≈ $4.47K |
+37.03% |
| 2002-12-31 | GBX26.79 Million ≈ $3.26K |
-31.76% |
| 2001-12-31 | GBX39.26 Million ≈ $4.78K |
+174.25% |
| 2000-12-31 | GBX14.32 Million ≈ $1.74K |
+211.10% |
| 1999-12-31 | GBX4.60 Million ≈ $559.93 |
-12.19% |
| 1998-12-31 | GBX5.24 Million ≈ $637.68 |
+63.68% |
| 1997-12-31 | GBX3.20 Million ≈ $389.59 |
+155.96% |
| 1996-12-31 | GBX1.25 Million ≈ $152.21 |
0.00% |
| 1996-09-30 | GBX1.25 Million ≈ $152.21 |
-- |
About Oxford BioMedica PLC
Oxford Biomedica plc, a contract development and manufacturing organization, focuses on delivering therapies to patients worldwide. Its LentiVector platform technology is a lentiviral vector based gene delivery system which is designed to overcome the safety and delivery problems associated with earlier generations of vector systems. The company operates in two segments, Platform and Product. The… Read more